Abstract: SA-PO1174
Peripheral Arterial Stiffness and Serum Acrolein in Nondialysis-Dependent CKD: Insights from a Cross-Sectional Study
Session Information
- CKD: SGLT2 Inhibitors and GLP-1 RAs for Kidney Health
November 08, 2025 | Location: Exhibit Hall, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: CKD (Non-Dialysis)
- 2302 CKD (Non-Dialysis): Clinical, Outcomes, and Trials
Authors
- Chang, Ho-Hsiang, Division of Nephrology, Buddhist Tzu Chi General Hospital, Hualien, Taiwan
- Hsu, Bang-Gee, Division of Nephrology, Buddhist Tzu Chi General Hospital, Hualien, Taiwan
Background
Peripheral arterial stiffness (PAS) is prevalent in patients with chronic kidney disease (CKD) and is associated with increased cardiovascular risk. Acrolein, a toxic aldehyde from oxidative stress, may contribute to vascular dysfunction. To examine the association between serum acrolein levels and PAS in non-dialysis CKD stage 3-5 patients.
Methods
We enrolled 204 CKD patients and classified them into PAS and control groups based on the cardio-ankle vascular index (CAVI). The CAVI was measured using the VaSera VS-1000 system, and PAS was defined as a CAVI ≥ 9.0 on either side. Serum acrolein levels were quantified using a commercial enzyme-linked immunosorbent assay.
Results
The PAS group (n = 90, 44.1%) was older (P = 0.023) and had higher left and right CAVI (P < 0.001), acrolein (P = 0.008), interleukin 6 (IL-6, P = 0.025), fasting glucose (P = 0.041), and spot urine to creatinine ratio (UPCR, P = 0.046) levels compared with patients without PAS. Serum acrolein was independently associated with PAS (odds ratio [OR]: 1.016, 95% confidence interval [CI]: 1.002–1.029, P = 0.023). Spearman's correlation analysis revealed a significant negative association between log-transformed acrolein (log-acrolein) level and CAVI on the left (r = 0.187, P = 0.008) and right (r = 0.168, P = 0.016). Serum acrolein level had an area under the receiver operating characteristic (AUC) curve of 0.609 (95% CI: 0.531−0.688, P = 0.008) for predicting PAS. The combined model of acrolein, age, glucose, IL-6, and UPCR showed the best discrimination (AUC = 0.688).
Conclusion
Elevated serum acrolein is significantly associated with PAS in non-dialysis CKD stage 3-5 patients. Acrolein may be a potential biomarker or therapeutic target in managing vascular stiffness in this population.